Related Experiment Video
Updated: Aug 6, 2026

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
Published on: December 20, 2017
CNS manifestations of Fabry's disease
Andreas Fellgiebel1, Matthias J Müller, Lionel Ginsberg
1Department of Psychiatry, University of Mainz, Mainz, Germany. fellgiebel@psychiatrie.klinik.uni-mainz.de
Insights
Fabry disease, a rare genetic disorder, significantly impacts the brain, causing strokes in young patients. Early diagnosis and monitoring are crucial, especially in women, for better management of this under-diagnosed condition.
Area of Science:
- Neurology
- Genetics
- Rare Diseases
Background:
- Fabry disease is a rare X-linked lysosomal storage disorder.
- It results from alpha-galactosidase A deficiency, causing glycosphingolipid accumulation.
- This accumulation affects multiple organs, including the brain, leading to cerebrovascular events.
Purpose of the Study:
- To highlight the significant prevalence of central nervous system (CNS) involvement in Fabry disease.
- To emphasize the under-diagnosis of Fabry disease, particularly in young stroke patients.
- To underscore the need for increased clinical attention and research into Fabry disease's neurological manifestations.
Main Methods:
- Review of existing neuropathological, neuroradiological, and functional studies.
- Analysis of recent research on CNS involvement in female Fabry disease patients.
- Examination of studies correlating Fabry disease with cryptogenic stroke in young individuals.
Main Results:
- Cerebral vasculopathy and ischaemic cerebrovascular events are common in Fabry disease.
- Women with Fabry disease exhibit a high prevalence of ischaemic stroke and CNS involvement.
- Fabry disease is frequently observed in young patients presenting with cryptogenic stroke.
Conclusions:
- Fabry disease should be considered in the differential diagnosis of stroke, especially in young patients.
- Further research is needed to monitor brain structural changes and CNS involvement.
- Enzyme-replacement therapy may offer benefits for cardiac and renal dysfunction, warranting further investigation for neurological effects.
Background:
Fabry's disease is a rare hereditary lysosomal storage disease with multiorgan involvement. Deficiency of alpha-galactosidase A activity leads to accumulation of neutral glycosphingolipids, especially in vascular endothelial and smooth-muscle cells. Along with progressive renal and cardiac dysfunction, stroke is a major and often life-threatening burden of the disease. Cerebral vasculopathy, confirmed by neuropathological, neuroradiological, and functional studies, occurs commonly and leads to ischaemic cerebrovascular events at an early age.
Recent Developments:
Fabry's disease is an X-linked disease and women have been regarded as only mildly affected carriers. However, research has shown a high prevalence of ischaemic stroke and transient ischaemic attacks, along with imaging evidence of CNS involvement, in female patients with the disease, which suggests that at least in a subgroup of clinically affected women the severity of CNS disease is comparable to that in men. Another study has shown a high prevalence of the disease in young patients of both sexes with cryptogenic stroke, emphasising the need for more clinical attention to be paid to this under-diagnosed disease. WHERE NEXT?: These new findings should be replicated in larger samples. Brain structural changes and CNS involvement in the disease need to be monitored carefully in follow-up studies to broaden our knowledge of the course of neurobiological changes and to identify potential effects of enzyme-replacement therapy, which is already showing some benefit in cardiac and renal dysfunction in the disease. Finally, a diagnosis of Fabry's disease should always be considered in young patients who have had a stroke.
More Related Videos
06:02Experimental Approaches for Biochemical Analysis of Glial Fibrillary Acidic Protein and Its Disease-associated Variants
Published on: November 28, 2025
09:32Bioluminescence Imaging of Neuroinflammation in Transgenic Mice After Peripheral Inoculation of Alpha-Synuclein Fibrils
Published on: April 13, 2017
Related Concept Videos
Multiple Sclerosis l: Introduction
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Hepatic Encephalopathy
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Alterations in Muscle Tone lll